These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36205826)

  • 41. [Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia].
    Li C; Geng SX; Li MM; Su F; Chen XM; Deng CX; Huang X; Lai PL; Weng JY; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):56-62. PubMed ID: 32027253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
    Moon Y; Kim MH; Kim HR; Ahn JY; Huh J; Huh JY; Han JH; Park JS; Cho SR
    Ann Lab Med; 2018 Sep; 38(5):481-483. PubMed ID: 29797820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.
    Tang G; Zhang L; Fu B; Hu J; Lu X; Hu S; Patel A; Goswami M; Khoury JD; Garcia-Manero G; Medeiros LJ; Wang SA
    Am J Hematol; 2014 Aug; 89(8):813-8. PubMed ID: 24782398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.
    Grignano E; Mekinian A; Braun T; Liozon E; Hamidou M; Decaux O; Puéchal X; Kahn JE; Schoindre Y; Rossignol J; Lortholary O; Lioger B; Hermine O; Park S; Ades L; Montestruc F; Ricard L; Gardin C; Fenaux P; Fain O;
    Leuk Res; 2016 Aug; 47():136-41. PubMed ID: 27337291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
    Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
    Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.
    Guru Murthy GS; Dhakal I; Mehta P
    Leuk Lymphoma; 2017 Jul; 58(7):1648-1654. PubMed ID: 27881041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype.
    Heibl S; Gisslinger B; Jäger E; Barna A; Gurbisz M; Stegemann M; Bettelheim P; Machherndl-Spandl S; Pfeilstöcker M; Nösslinger T; Uyanik G; Hoermann G; Stauder R; Thaler J; Kusec R; Valent P; Gisslinger H; Geissler K
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32674283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Models of Prognostication in Chronic Myelomonocytic Leukemia.
    Onida F
    Curr Hematol Malig Rep; 2017 Dec; 12(6):513-521. PubMed ID: 29064026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Indurated erythema as the presenting form of a case of chronic myelomonocytic leukemia].
    Raya Sánchez JM; Rodríguez Salazar MJ; Brito Barroso ML; Guimerá Martín-Neda F; Alvarez-Argüelles Cabrera H; Hernández Nieto L
    An Med Interna; 2004 Jan; 21(1):17-9. PubMed ID: 15195480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience.
    Alsahlawi A; Alkhateeb H; Patnaik M; Begna K; Elliott M; Hogan WJ; Litzow M; Al-Kali A
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):e39-41. PubMed ID: 25027568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bullous pyoderma gangrenosum complicated by disseminated intravascular coagulation with subsequent myelodysplastic syndrome (chronic myelomonocytic leukemia).
    Rogalski C; Paasch U; Glander HJ; Haustein UF
    J Dermatol; 2003 Jan; 30(1):59-63. PubMed ID: 12598711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How I diagnose and treat chronic myelomonocytic leukemia.
    Patnaik MM
    Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience.
    Subari S; Patnaik M; Alfakara D; Gangat N; Elliott M; Hogan W; Litzow M; Al-Kali A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):546-9. PubMed ID: 26189785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; D'Elia GM; Alimena G
    Leuk Lymphoma; 2008 Jul; 49(7):1292-6. PubMed ID: 18604717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic myelomonocytic leukemia - a review.
    Thomopoulos TP; Bouhla A; Papageorgiou SG; Pappa V
    Expert Rev Hematol; 2021 Jan; 14(1):59-77. PubMed ID: 33275852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age-related mutations and chronic myelomonocytic leukemia.
    Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
    Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.